Prestige Consumer Healthcare Q1 revenue $279.3M (+0.8% YoY); reaffirms FY2024 outlook

Prestige Consumer Healthcare Inc.

2024-Q1 EPS reported $1.06 revenue$279,309,000

Revenue $279.3M, up 0.8% YoY (1.8% ex-FX); net income $53.3M, diluted EPS $1.06 vs $1.09 prior year.
North American OTC revenue $246.1M (+1.5%); International OTC $33.2M, down from $34.5M on $1.9M FX headwind.
Completed $25M share repurchase (~0.4M shares); net debt ~$1.3B, leverage ratio 3.2x.
Reaffirmed FY2024 outlook: revenue $1,135-1,140M, diluted EPS $4.27-4.32, free cash flow $240M+.
Free cash flow $46.6M in Q1 vs $57.2M prior year, impacted by working capital timing.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Prestige Consumer Healthcare Inc. reported the fiscal quarter ended June 30, 2023 results: revenue $279.3 million, net income $53.3 million, EPS $1.06. Guidance reaffirmed.

Period: the fiscal quarter ended June 30, 2023
Revenue: $279.3 million
Net income: $53.3 million
EPS: $1.06
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Reported revenues in the first quarter of fiscal 2024 of $279.3 million increased 0.8% from $277.1 million in the first quarter of fiscal 2023.

View on SEC.gov

Browse all earnings releases →

Prestige Consumer Healthcare Inc. filing history →

Source: SEC EDGAR

accession 0001295947-23-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.